NCT05687123 2026-03-19
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
24 trialsNCT03375320 2026-03-18
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05988918 2026-03-06
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT06943755 2026-02-27
STELLAR-311
Exelixis
Phase 2/3 Recruiting
NCT01824875 2026-02-25
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04924075 2026-02-24
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT03879694 2026-02-06
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT07273409 2026-01-22
PANTODON
Uppsala University
Phase NA Recruiting
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT07328607 2026-01-21
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
Minia University
Phase NA Recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT03891784 2026-01-14
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
Phase 2 Active not recruiting
NCT06663072 2026-01-09
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
University of Chicago
Phase 1 Recruiting
NCT06881992 2025-12-30
Tumor HI
Rezolute
Phase 3 Recruiting
NCT05040360 2025-12-15
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06148636 2025-11-04
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
University of Iowa
Phase EARLY_PHASE1 Active not recruiting
NCT02159989 2025-10-20
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT07121478 2025-10-01
Patients With High-grade Pancreatic Neuroendocrine Tumors
National Cancer Center, Korea
Phase 2 Enrolling by invitation
NCT07165132 2025-09-10
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Phase 1 Not yet recruiting
NCT04520932 2025-05-25
RFANET
Institut Paoli-Calmettes
Phase NA Recruiting
NCT05247905 2025-04-02
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting